Advances of Immune Checkpoint Inhibitors in Tumor Immunotherapy

5th Annual International Conference on Material Science and Environmental Engineering

材料科学;生态环境科学

Guo, Qiao^1

School of Life Sciences, Sun Yat-sen University, Guangzhou, China^1

关键词: Adaptive immune response;    Cancer immunotherapy;    Cell surface molecules;    Combination therapy;    Conventional treatments;    Therapeutic antibodies;    Tumor immunotherapy;    Tumor microenvironment;   

Others  :  https://iopscience.iop.org/article/10.1088/1757-899X/301/1/012020/pdf
DOI  :  10.1088/1757-899X/301/1/012020

来源: IOP

【 摘 要 】

Immune checkpoints are cell surface molecules that can fine-tune the immune responses, they are crucial for modulating the duration and amplitude of immune reactions while maintaining self-tolerance in order to minimize autoimmune responses. Numerous studies have demonstrated that tumors cells can directly express immune-checkpoint molecules, or induce many inhibitory molecules expression in the tumor microenvironment to inhibit the anti-tumor immunity. Releasing these brakes has emerged as an exciting strategy to cure cancer. In the past few years, clinical trials with therapeutic antibodies targeting to the checkpoint molecules CTLA-4 and PD-1 have rekindled the hope for cancer immunotherapy. In contrast to the conventional treatment, checkpoint inhibitors induce broad and durable antitumor responses. In the future, treatment may involve combination therapy to target different checkpoint molecules and stages of the adaptive immune responses. In this review, we summarized the recent advances of the study and development of other checkpoint molecules in tumor immunotherapy.